Article

Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer

2023-01-18

Abstract excerpt

<title>Abstract</title> <p>Background: Novel antibody-drug conjugates (ADCs) show activity in HER2-low advanced breast cancer. We examined differences in HER2 expression between primary tumors and distant metastases, particularly within the HER2-negative cohort (HER2-low and HER2-zero). Patients and Methods: The retrospective study included 191 consecutive paired samples of primary breast cancer (BC) and distant...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 467c3e14-a948-505e-b8ed-f4c5778b255a
DOI: 10.21203/rs.3.rs-2478913/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discordance of HER2-low between primary tumors and matched distant metastases in breast cancerDOI 10.21203/rs.3.rs-2478913/v1Read

Impact of HER2-low Breast Cancer on Survival in Denmark: A Nationwide Investigation (2007-2019)Semantic proximity Read

Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterationsSemantic proximity Read

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read

Low and Ultra-low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic SubtypesSemantic proximity Read

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Semantic proximity Read

Receptor discordance and phenotype change in metastatic breast cancer.Semantic proximity Read

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary.Semantic proximity Read

Single HER2-Positive Tumor Cells are Detected in Initially HER2-Negative Breast Carcinomas using the DEPArray™–HER2-FISH WorkflowSemantic proximity Read

Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast CancerSemantic proximity Read

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity Read

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read